Aratana Therapeutics to Report Third Quarter 2016 Financial Results

Mittwoch, 19.10.2016 14:35 von

PR Newswire

LEAWOOD, Kan., Oct. 19, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Friday, November 4, 2016 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2016.

Aratana Therapeutics logo

Interested participants and investors may access the audio webcast or use the conference call dial-in:

     1 (866) 364-3820 (U.S.)
     1 (855) 669-9657 (Canada)
     1 (412) 902-4210 (International)

A replay of the third quarter results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10095395:

     1 (877) 344-7529 (U.S.)
     1 (855) 669-9658 (Canada
     1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit

For investor inquires:
Craig Tooman 
(913) 353-1026

For media inquiries:
Rachel Reiff
(913) 353-1050

Logo -

To view the original version on PR Newswire, visit:

SOURCE Aratana Therapeutics, Inc.